High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
Top Cited Papers
- 1 June 2015
- journal article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (6), 2231-2238
- https://doi.org/10.1210/jc.2015-1966
Abstract
Context and Objective: Nonalcoholic fatty liver disease (NAFLD) and its more severe form with steatohepatitis (NASH) are common in patients with type 2 diabetes mellitus (T2DM). However, they are usually believed to largely affect those with elevated aminotransferases. The aim of this study was to determine the prevalence of NAFLD by the gold standard, liver magnetic resonance spectroscopy (1H-MRS) in patients with T2DM and normal aminotransferases, and to characterize their metabolic profile. Participants and Methods: We recruited 103 patients with T2DM and normal plasma aminotransferases (age, 60 ± 8 y; body mass index [BMI], 33 ± 5 kg/m2; glycated hemoglobin [A1c], 7.6 ± 1.3%). We measured the following: 1) liver triglyceride content by 1H-MRS; 2) systemic insulin sensitivity (homeostasis model assessment-insulin resistance); and 3) adipose tissue insulin resistance, both fasting (as the adipose tissue insulin resistance index: fasting plasma free fatty acids [FFA] × insulin) and during an oral glucose tolerance test (as the suppression of FFA). Results: The prevalence of NAFLD and NASH were much higher than expected (50% and 56% of NAFLD patients, respectively). The prevalence of NAFLD was higher in obese compared with nonobese patients as well as with increasing BMI (P = .001 for trend). Higher plasma A1c was associated with a greater prevalence of NAFLD and worse liver triglyceride accumulation (P = .01). Compared with nonobese patients without NAFLD, patients with NAFLD had severe systemic (liver/muscle) and, particularly, adipose tissue (fasting/postprandial) insulin resistance (all P < .01). Conclusions: The prevalence of NAFLD is much higher than previously believed in overweight/obese patients with T2DM and normal aminotransferases. Moreover, many are at increased risk of NASH. Physicians should have a lower threshold for screening patients with T2DM for NAFLD/NASH.Keywords
This publication has 36 references indexed in Scilit:
- Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)Diabetes Care, 2012
- Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatmentNature Reviews Endocrinology, 2011
- Endpoints and clinical trial design for nonalcoholic steatohepatitisJournal of Hepatology, 2011
- Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes StudyDiabetes Care, 2011
- Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factorsLiver International, 2011
- Combined Effect of Nonalcoholic Fatty Liver Disease and Impaired Fasting Glucose on the Development of Type 2 DiabetesDiabetes Care, 2011
- Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver diseaseJournal of Hepatology, 2010
- Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitusLiver International, 2008
- Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver DiseaseDiabetes Care, 2007
- Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver diseaseJournal of Hepatology, 2005